Individualizing Insulin Therapy in Type 2 Diabetes

06/12/2015 - Web-Based

Background and Instructions:

This learning outcomes survey is designed to determine the educational effectiveness of this CME activity; and specifically, the capacity for this CME engagement to improve knowledge and clinical performance gaps. The results of the pre-program test will be compared with the results of this follow-up test, as well as additional tests that will be e-mailed to you at 4 weeks, and then again, at 8 weeks following completion and submission of the test below.

To complete Phase 1 of this Clinical Performance and Knowledge Gap Assessment Tool, please indicate your answer for each of the questions below. There is only one correct answer for each question.

Thank you,
CMEducation Resources
====================================================================================

A. Clinical Questions

1. With respect to recommendations contained in the ADA/EASD Guidelines issued on April 19, 2012, all of the following are true for managing older patients with T2D, EXCEPT:

2. Which of the following statements regarding key considerations in the management of type 2 diabetes is FALSE?

3. Which of the following statements regarding the ADA/EASD guidelines and treatment algorithm is TRUE?

5. 5. Which of the following statements regarding the early initiation, addition, or intensification of insulin therapy in type 2 diabetes is FALSE?

6. When initiating insulin therapy in patients with type 2 diabetes, patients should be advised to maintain regular eating habits and exercise schedules centered around their insulin treatment regimen.

7. All of the following should be a primary consideration when designing/adjusting insulin regimens in patients with type 2 diabetes EXCEPT:

8. TK is a 64-year old woman with a 3-year history of type 2 diabetes. Despite losing 10 pounds in the past year, her most recent A1c is 7.9%. Her current medication regimen includes metformin and a sulfonylurea. You decide to add insulin treatment to her regimen. Which of the following is the MOST appropriate next step in therapy for TK?

9. Rapid-acting insulin analogues control post-prandial glucose levels better than regular insulin, but cause more hypoglycemia.

10. Which of the following is LEAST likely to contribute to the general delay in initiating insulin therapy in patients with type 2 diabetes?

11. In which of the following patients with type 2 diabetes would it be MOST appropriate to initiate insulin therapy with glargine U-300?

12. GG is a 68-year old woman with a 3-year history of type 2 diabetes. Her A1c is 8.1% and she is currently on metformin, a sulfonylurea, and bedtime basal insulin. Her fasting plasma glucose levels are consistently around 110 mg/dL and her postprandial levels are around 180 mg/dL. Which of the following is the MOST appropriate next step in therapy for GG?

13. Which of the following statements about U-100 glargine (basal insulin) versus U-300 glargine (basal insulin) is FALSE?

B. Subjective Practice Assessment/Attitudes/Perceptions/Demographic

1. Approximately how many patients with type 2 diabetes do you see EACH WEEK?

2. When managing your patients with type 2 diabetes, to which of the following national guidelines/recommendations are you most likely to refer?

3. How confident are you in your ability to appropriately manage your patients with type 2 diabetes who are not achieving glycemic targets?

4. How confident are you in your ability to set appropriate treatment targets in your patients with type 2 diabetes based on their individualized needs?

5. How confident are you in your ability to appropriately identify patients with type 2 diabetes who may benefit from insulin therapy?

6. Currently, how often do you initiate insulin therapy as second or third-line treatments in your patients with type 2 diabetes who are not achieving adequate glycemic control on oral therapies?

Please indicate your specialty:

Your Information

Please provide your email address to complete this survey form. Completed surveys will be assigned an ID number that will allow us to process your survey responses anonymously and compare pooled pre-program survey results with post-program survey results to measure ongoing, enduring learning. Your email address will be used to communicate information on future surveys and send a final outcomes report. Thank you.